Recent News

New Tool May Aid in Identifying Subtypes of Ovarian Cancer

Targeted Therapy With Crizotinib for ROS1-Mutant Ovarian Cancer: Case Study

Novel First-in-Class Agent Shows Activity in High-Grade Serous Ovarian Cancer

NCI Funds Projects to Study Racial Disparities Among Women With Ovarian Cancer

Noninvasive Early Molecular Diagnosis of High-Grade Serous Epithelial Ovarian Cancer

Epithelial Ovarian Cancer: Risk Factors May Explain Racial Differences in Incidence

Novel ATR Inhibitor Under Study in Platinum-Resistant High-Grade Serous Ovarian Cancer

Ovarian Cancer and COVID-19: Challenges in Surgical Treatment

AACR II: Antibody-Drug Conjugate Targets CLDN6/9 in Epithelial Ovarian Cancer

AACR II: Synergistic Effects of Crizotinib and Olaparib in Ovarian Cancer

Study Assesses Risks Associated With Minimally Invasive Surgery for Early-Stage Ovarian Cancer

COVID-19 and Gynecologic Cancer: SGO Expert Panel Offers Clinical Considerations

BRCA-Mutated Ovarian Cancer and COVID-19: A Potential Alternative to Surgery

HIPEC Plus Secondary Cytoreductive Surgery for Resistant Ovarian Cancer

AACR II: Do Ovarian Cancer Survivors Have an Increased Risk for Type 2 Diabetes?

ASCO20: Is Quality of Life Shaped by Sleep Schedules in Ovarian Cancer Survivors?

AACR II: Lipophilic Statins and Ovarian Cancer Mortality

ASCO20: Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer

Hospital Case Load May Affect Survival in Ovarian Cancer

ASCO20: Autologous Tumor Immunotherapy Plus Atezolizumab in Recurrent Ovarian Cancer

ASCO20: Antibody-Drug Conjugate Plus Bevacizumab in Platinum-Agnostic Ovarian Cancer

ASCO20: Does Secondary Cytoreductive Surgery Offer Survival Benefit in Recurrent Ovarian Cancer?

ASCO20: Comparing Cediranib Regimens With Standard Chemotherapy in Recurrent Ovarian Cancer

Can Viral Immunotherapy Reverse Platinum Resistance in Ovarian Cancer?

ASCO20: ‘Modest Antitumor Activity’ for Pembrolizumab in Recurrent Ovarian Cancer

Does Trametinib Improve Outcomes in Low-Grade Serous Ovarian Cancer?

Combination Therapy of Paclitaxel, Carboplatin, and Pembrolizumab in Ovarian Cancer

Sequential Chemotherapy for Ovarian Cancer

Video-Assisted Genetic Counseling for Patients With Ovarian Cancer

ASCO20 Preview: Survival Benefit Reported With Maintenance Olaparib in Advanced Ovarian Cancer

AACR 2020: Dendritic Cell Vaccines for Advanced Ovarian Cancers

Olaparib Plus Bevacizumab Receives FDA Approval for Ovarian Cancer Maintenance Therapy

SGO 2020: Updated PAOLA-1 Data Support Maintenance Therapy for High-Grade Serous Ovarian Cancer

AACR 2020: Durvalumab Combined With Chemotherapy for Ovarian Cancer

Racial Disparity in Clinical Trials of Immunotherapeutics for Ovarian Cancer

Niraparib Approved by FDA as Maintenance Treatment of Advanced Ovarian Cancer

Predictors of Thromboembolic Events in Patients With Epithelial Ovarian Carcinoma

SGO 2020: Phase III Data Support Benefit of Niraparib in Ovarian Cancer

ACC 2020: Case Study of Metastatic Ovarian Cancer With Syncope

SGO 2020: For BRCA-Mutation Carriers, Breast Cancer May Follow Ovarian Cancer

Managing Patients With Ovarian Cancer During COVID-19 Pandemic

Preclinical Study of TGF-β Inhibition in Ovarian Cancer

NCCN Collaborative Projects in Advanced Ovarian Cancer

Can Ovarian RADS MRI Identify Ovarian Cancer in Indeterminate Masses?

FDA Accepts sNDA for Niraparib in First-Line Maintenance Treatment of Ovarian Cancer

Fox Chase Researchers Receive Grant to Study High-Grade Serous Ovarian Cancer